In Personalized Selection of Immunotherapy Strategies in Metastatic NSCLC and Future Evidence Gaps, our experts delve into ...

In this analysis from the phase 3 EMPOWER‐Lung 1 study, researchers reported on quality of life in patients with advanced non‐small cell lung cancer and PD-L1 expression of 50% or more.

The DEPEND study demonstrates that checkpoint inhibitor nivolumab (Opdivo®) works best with high levels of PD-L1 biomarker, but does not work well with low levels of PD-L1 Multikine* is uniquely ...

A protein already targeted by FDA-approved cancer drugs may also help the body fight influenza, according to new research ...

A new analysis of real-world data show that just as in solid tumors, higher tumor mutational burden (TMB) and PD-L1 expression in blood cancers are linked to less-optimistic prognoses. Their ...

The efficacy of molecule-matched treatment on hyperprogressive disease after immunotherapy: A retrospective study from the Molecular Tumor Board registry. This is an ASCO Meeting Abstract from the ...

Effect of low-dose rapamycin on the therapeutic response to radio-immunotherapy in hepatocellular carcinoma. Multi-omics analysis of PD-1 inhibitor combination in neoadjuvant treatment of pMMR/MSS ...

Treatment responses to Xalkori were not affected by PD-L1 expression in patients with advanced non-small cell lung cancer and ROS1 rearrangements. Patients with advanced non-small cell lung cancer ...